Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia

Seligman, Renato; Papassotiriou, Jana; Morgenthaler, Nils G.; Meisner, Michael; Teixeira, Paulo José Zimermann

doi:10.1186/cc6780

Cited by 105 publications

(99 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An elevated cytokine level, especially IL-6, correlates with disease severity and maybe more predictive of an early clinical deterioration than older biomarkers (29,30). Other note worthy biomarkers include hormone surrogates [pro-adrenomedullin (ProADM), copeptin], markers of coagulation (D-dimer) among others (48,(78)(79)(80).…”

Section: Novel Biomarkersmentioning

confidence: 99%

“…ProADM is a fragment of the vasodilator and bacteriocidal hormone adrenomedullin, particularly elevated in sepsis (84)(85)(86). Copeptin, a precursor of arginine vasopressin is raised in a variety of diseases including congestive heart failure but levels correlate significantly with poor outcomes in sepsis and CAP (80,(87)(88)(89). Pro-ADM and Copeptin have been shown to be strong predictors of early mortality and adverse outcomes, potentially more than PCT and CRP.…”

Section: Novel Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of treatment failure and clinical stability in patients with community acquired pneumonia

Morley¹,

Torres²,

Cillóniz³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Community acquired pneumonia (CAP) is the leading infectious cause of mortality worldwide with approximately 10% of patients hospitalized requiring intensive care unit (ICU) admission. The ability to predict clinical stability (CS) and treatment failure (TF) enables the clinician to alter antibiotics appropriately, facilitate a timely ICU admission, or arrange a suitable discharge. The detection of CS and TF can be difficult and changes in clinical signs may be subtle or delayed. Thus clinical scores and biomarkers are routinely used to identify severity and monitor clinical progression. The evidence, however, is vast and the definitive role of these systems is at times difficult to elucidate. The aim of this review is to analyse the current literature and to provide a rational and clinically focused view of the predictive utility of various systems used to identify CS and TF in CAP.

show abstract

Section: Novel Biomarkersmentioning

confidence: 99%

Section: Novel Biomarkersmentioning

confidence: 99%

Predictors of treatment failure and clinical stability in patients with community acquired pneumonia

Morley¹,

Torres²,

Cillóniz³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…These studies include patients with sepsis [16,17], pneumonia and lower respiratory tract infections [16,18,19], stroke [20,21], acute myocardial infarction and congestive heart failure [22][23][24][25], as well as diabetes type 2 [26], metabolic syndrome [27] and diabetes insipidus [28]. Also in primary care, copeptin was found to predict risk in patients with heart failure [29,30], but there is no comprehensive data assessing the usefulness of serum copeptin levels as a general "risk marker" in a patient sample from primary care contacting general practitioners (GPs) due to acute respiratory tract infections (ARTIs).…”

Section: Introductionmentioning

confidence: 99%

Copeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study

Odermatt

Bolliger

Hersberger

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Copeptin, the C-terminal part of the arginine vasopressin (AVP) precursor peptide, is secreted in response to stress and correlates with adverse clinical outcomes in the acute-care hospital setting. There are no comprehensive data regarding its prognostic value in the community. We evaluated associations of copeptin levels with 10-year mortality in patients visiting their general practitioner (GP) for a respiratory infection included in a previous trial. Methods: This is a post hoc analysis including data from 359 patients included in the PARTI trial. Copeptin was measured in batch-analysis on admission and after 7 days. We calculated Cox regression models and area under the receiver operating characteristic curve (AUC) to assess an association of copeptin with mortality and adverse outcome. Follow-up data were collected by GP, patient and relative tracing through phone interviews 10 years after trial inclusion. Results: After a median follow-up of 10.0 years, mortality was 9.8%. Median admission copeptin levels (pmol/L) were significantly elevated in non-survivors compared to survivors (13.8, IQR 5.9-27.8; vs. 6.3 IQR 4.1-11.5; p < 0.001). Admission copeptin levels were associated with 10-year all-cause mortality [age-adjusted hazard ratio 1.7 (95% CI, 1.2-2.5); p < 0.001, AUC 0.68]. Results were similar for discharge copeptin levels. Copeptin also predicted adverse outcomes defined as death, pulmonary embolism and major adverse cardiac and cerebrovascular events. Conclusions: In a sample of community-dwelling patients visiting their GP for a respiratory infection, copeptin levels were associated with 10-year all-cause mortality. In conjunction with traditional risk factors, this marker may help to better direct preventive measures in this population.

show abstract

“…Measurement of copeptin has also been suggested in the early exclusion of acute myocardial infarction among patients with suspected acute coronary syndrome [5,6,10]. In addition, copeptin measurement provides prognostic information in several acute conditions such as myocardial infarction [11], heart failure [12][13][14][15][16], infection [17][18][19], stroke [20,21], traumatic…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a Sensitive Copeptin Assay for Clinical Measurement

Terzic¹,

Johansson-Fällgren²,

Ragnarsson³

et al. 2012

TOCCHEMJ

View full text Add to dashboard Cite

Abstract:Background: Copeptin, a marker of vasopressin production, has been introduced for earlier diagnosis of acute myocardial infarction and other clinical emergencies. We evaluated the analytical performance of a new generation copeptin assay in an inter-laboratory trial.Methods: Precision, linearity range, carry-over contamination, the limit of blank and an inter-laboratory comparison trial for the copeptin US KRYPTOR assay were performed on the B·R·A·H·M·S KRYPTOR compact PLUS.Results: The intra-assay imprecision (CVs) was 12.6-2.2% and total imprecision over five days was 12.3-4.3% between 3.1 and 18.2 pmol/L. The assay had excellent linearity between 7-222 pmol/L. The limit of blank was 2.5 pmol/L and the limit of detection was 3.2 pmol/L, but was dependent on the analyte-free material used. No significant difference between sample type, such as serum or different types of plasma or reagent lots, was noted. The copeptin results remained unchanged upon five repeated freeze-thaw cycles. A set of patient samples with a mean copeptin concentration of 2.1-61 pmol/L run at two separate sites showed close correlation (r 2 =0.99, slope=1.01, intercept=0.35), indicating comparable results across laboratories. Conclusion:The new ultrasensitive copeptin KRYPTOR assay shows excellent inter-lab precision, opening up the possibility for international guidelines to exclude acute myocardial infarction.

show abstract

Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia

Abstract: Background The present study sought to investigate the correlation of copeptin with the severity of septic status in patients with ventilator-associated pneumonia (VAP), and to analyze the usefulness of copeptin as a predictor of mortality in VAP.

Cited by 105 publications

References 25 publications

Predictors of treatment failure and clinical stability in patients with community acquired pneumonia

Predictors of treatment failure and clinical stability in patients with community acquired pneumonia

Copeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study

Evaluation of a Sensitive Copeptin Assay for Clinical Measurement

Contact Info

Product

Resources

About